Small Animal Imaging Platforms

Small animal imaging platforms have transformed how researchers visualize tumor biology, pharmacokinetics, and therapeutic responses in living subjects over time. Alfa Cytolog leverages state-of-the-art multimodal imaging infrastructure to deliver longitudinal, quantitative preclinical data that bridges the gap between bench discovery and bedside application.

Overview of Small Animal Imaging Platforms

Preclinical small animal imaging encompasses a diverse suite of non-invasive technologies adapted for rodent models, including micro-PET, micro-SPECT, micro-CT, micro-MRI, optical imaging (bioluminescence and fluorescence), photoacoustic imaging, and high-frequency ultrasound. Each modality offers distinct spatial resolution, sensitivity, and contrast mechanisms: optical systems excel at detecting molecular reporters at picomolar sensitivity but with limited tissue penetration; micro-CT provides high-resolution anatomical detail ideal for skeletal and pulmonary assessments; micro-MRI delivers exceptional soft-tissue contrast without ionizing radiation, enabling repeated longitudinal studies of brain and abdominal tumors; while nuclear imaging modalities such as PET and SPECT quantify tracer distribution, metabolism, and receptor occupancy across the whole body with unmatched molecular sensitivity.

Fig 1. Multimodal imaging modalities for small animal imaging. (Youn, Hyewon, et al., 2012)

The convergence of these technologies into hybrid and multimodal systems—such as PET/CT, PET/MRI, and SPECT/CT—has become a defining trend in translational oncology research. By co-registering functional molecular data with high-resolution anatomical maps, researchers can precisely localize tracer uptake within tumor microenvironments, monitor vascular changes, assess hypoxia, and evaluate immune cell infiltration over the course of a therapeutic regimen. This integration not only improves the accuracy of pharmacodynamic readouts but also supports the 3Rs principles by reducing the total number of animals required per study while maximizing the information extracted from each subject.

Radiopharmaceutical Development and the Rise of Theranostics

The radiopharmaceutical landscape is undergoing a profound shift toward theranostics—the paired use of diagnostic and therapeutic radionuclides targeting the same biological marker. In oncology, this paradigm enables clinicians and researchers to first image tumor-specific receptors or antigens using low-dose diagnostic tracers, then treat the same lesions with high-energy therapeutic isotopes. Preclinical imaging platforms play a pivotal role in validating these agents before human translation, allowing investigators to characterize biodistribution, tumor uptake kinetics, off-target accumulation, and dosimetry in living animal models.

Our Services

At Alfa Cytolog, we recognize that robust imaging data are the cornerstone of successful translational oncology programs. Our integrated small animal imaging platforms are designed to support every stage of your drug development pipeline—from early target validation and lead optimization through to efficacy and toxicity assessments in sophisticated tumor models. By combining cutting-edge instrumentation with expert study design and quantitative image analysis, we deliver actionable insights that de-risk your therapeutic candidates and accelerate their path toward clinical evaluation.

Our Small Animal Imaging Services

Workflow of Small Animal Imaging Platforms

A successful preclinical imaging study begins with clear scientific objectives and ends with validated, quantitative data that inform downstream decisions. At Alfa Cytolog, each imaging project follows a structured yet flexible workflow designed to maximize data quality, animal welfare, and translational relevance.

Step 1: Study Design & Consultation

Our team collaborates with you to define imaging endpoints, select the most appropriate modality or multimodal combination, and establish power calculations based on expected effect sizes and historical variability.

Step 2: Model Selection & Validation

We identify or develop the optimal tumor model—xenograft, syngeneic, orthotopic, or genetically engineered—and confirm baseline imaging characteristics such as tumor take rate, growth kinetics, and background signal.

Step 3: Tracer / Contrast Agent Preparation

For nuclear or optical studies, we assist in radiolabeling, fluorescent tagging, or contrast formulation, followed by quality control to ensure specific activity, purity, and stability prior to administration.

Step 4: In Vivo Imaging Acquisition

Animals undergo scheduled imaging sessions under controlled anesthesia and physiological monitoring. Scan parameters are optimized for each modality to balance spatial resolution, sensitivity, and scan duration.

Step 5: Image Reconstruction & Co-Registration

Raw data are reconstructed using platform-specific algorithms, with multimodal datasets spatially aligned to anatomical references for precise localization of functional signals within tumor and normal tissues.

Step 6: Quantitative Analysis & Biomarker Extraction

We perform standardized segmentation, extract volumetric and radiomics features, generate time-activity curves, and calculate pharmacokinetic parameters to yield statistically robust endpoints.

Step 7: Data Interpretation & Reporting

Results are compiled into comprehensive reports with publication-ready figures, statistical summaries, and mechanistic interpretations, delivered with full traceability for regulatory and peer-review purposes.

Applications of Small Animal Imaging Platforms

Contact Us

Ready to elevate your preclinical oncology program with quantitative, multimodal imaging insights? Reach out to our team today to discuss your study objectives, explore customized imaging workflows, and receive a detailed project proposal. Contact us now and let Alfa Cytolog be your trusted partner in accelerating the journey from preclinical discovery to clinical success.

For research use only. Not intended for any clinical use.